Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).

Respir Res · 2015 · PMC4531806 · PMID 26233481

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The rate of HCRU exacerbations of any severity was also lower (−24 %) with FDC 400/12 μg compared with placebo; however, the differences did not reach statistical significance (Fig. 4a ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.